If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 47
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patie
Objective
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Protocol No
BEIGENE-BGB-11417-105
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B
Objective
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Categories
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Objective
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma?
We are doing this study to find out if this approach is better or worse than the usual approach to treating low tumor burden follicular lymphoma.
We are doing this study to find out if this approach is better or worse than the usual approach to treating low tumor burden follicular lymphoma.
Protocol No
SWOG-S2308
Categories
Feasibility of Assessing Physical Activity, Fatigue, and Inflammatory Biomarkers Among Chronic Myeloid Leukemia Patients with TKI-Induced Fatigue
Objective
MoveCML-DBS
Protocol No
IIT-MORELLI-MOVECML-DBS
Categories
A Controlled Multi-Arm Phase 1 Umbrella Study Evaluating the Safety and Feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 Positive Patients Undergoing Haploidentical Allogeneic Periphera
Objective
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
Protocol No
TSCAN-001
Categories
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients A
Objective
Testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia
Protocol No
SWOG-MM1YA-S01
Categories
Phase I Study of Iadademstat with Hypomethylating Agent in Patients with Myelodysplastic Syndrome
Objective
Phase I Study of Iadademstat with Azacitidine in Patients with Myelodysplastic Syndrome
Protocol No
IIT-GURU-IADADEMSTAT-MDS
Categories
A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Objective
A Study of Abbvie M22-947 in Patients with Relapsed Refractory Multiple Myeloma
Protocol No
ABBVIE-M22-947
Categories
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Objective
Study of stem cell transplant for patients with T cell lymphoma in remission after induction therapy
Protocol No
ECOG-EA4232
Categories
A Phase 3, Open-Label, Multicenter Study of I-124 evuzamitide as an Imaging Agent for the Diagnosis of Cardiac Amyloidosis using Positron Emission Tomography Computed Tomography (PET/CT)
Objective
REVEAL - Research with I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
Protocol No
ATTRALUS-REVEAL-AT01-301
Categories